174 related articles for article (PubMed ID: 38159023)
1. [Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review].
Demidova TY; Ushanova FO
Ter Arkh; 2023 Nov; 95(10):888-895. PubMed ID: 38159023
[TBL] [Abstract][Full Text] [Related]
2. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.
Leoni S; Tovoli F; Napoli L; Serio I; Ferri S; Bolondi L
World J Gastroenterol; 2018 Aug; 24(30):3361-3373. PubMed ID: 30122876
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
[TBL] [Abstract][Full Text] [Related]
4. Modern approach to the clinical management of non-alcoholic fatty liver disease.
Del Ben M; Polimeni L; Baratta F; Pastori D; Loffredo L; Angelico F
World J Gastroenterol; 2014 Jul; 20(26):8341-50. PubMed ID: 25024593
[TBL] [Abstract][Full Text] [Related]
5. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options.
Grander C; Grabherr F; Tilg H
Cardiovasc Res; 2023 Aug; 119(9):1787-1798. PubMed ID: 37364164
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
Pallayova M; Taheri S
Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
[TBL] [Abstract][Full Text] [Related]
7. [The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities].
Maevskaya MV; Kotovskaya YV; Ivashkin VT; Tkacheva ON; Troshina EA; Shestakova MV; Breder VV; Geyvandova NI; Doshchitsin VL; Dudinskaya EN; Ershova EV; Kodzoeva KB; Komshilova KA; Korochanskaya NV; Mayorov AY; Mishina EE; Nadinskaya MY; Nikitin IG; Pogosova NV; Tarzimanova AI; Shamkhalova MS
Ter Arkh; 2022 Feb; 94(2):216-253. PubMed ID: 36286746
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and management of non-alcoholic fatty liver disease.
Jennison E; Patel J; Scorletti E; Byrne CD
Postgrad Med J; 2019 Jun; 95(1124):314-322. PubMed ID: 31085617
[TBL] [Abstract][Full Text] [Related]
9. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.
Milić S; Lulić D; Štimac D
World J Gastroenterol; 2014 Jul; 20(28):9330-7. PubMed ID: 25071327
[TBL] [Abstract][Full Text] [Related]
11. Non-Alcoholic Fatty Liver Disease.
Brůha R
Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease: Evolving paradigms.
Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity?
Schröder B; Kahl S; Roden M
Liver Int; 2021 Jun; 41 Suppl 1():105-111. PubMed ID: 34155798
[TBL] [Abstract][Full Text] [Related]
14. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
Clemente MG; Mandato C; Poeta M; Vajro P
World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
Makri E; Goulas A; Polyzos SA
Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
[TBL] [Abstract][Full Text] [Related]
16. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic fatty liver disease as a multi-systemic disease.
Fotbolcu H; Zorlu E
World J Gastroenterol; 2016 Apr; 22(16):4079-90. PubMed ID: 27122660
[TBL] [Abstract][Full Text] [Related]
18. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.
Wang XC; Gusdon AM; Liu H; Qu S
World J Gastroenterol; 2014 Oct; 20(40):14821-30. PubMed ID: 25356042
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Syndrome: Nonalcoholic Fatty Liver Disease.
Williams T
FP Essent; 2015 Aug; 435():24-9. PubMed ID: 26280342
[TBL] [Abstract][Full Text] [Related]
20. [The diagnostics and clinical pattern of nonalcoholic fatty liver disease in patients with pre-diabetes and type 2 diabetes and obesity].
Чубірко КІ
Wiad Lek; 2017; 70(2):208-212. PubMed ID: 28511161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
